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ABSTRACT 
Objective: The aim of this work was to formulate the antiglaucoma drug acetazolamide as ocular nanoemulsion of high therapeutic efficacy and 
prolonged effect. 
Methods: Eighteen nanoemulsion formulaions consisting of different oils, surfactants and cosurfactants at various ratios and constant water 
content (39%) were prepared based on their constructed pseudoternary-phase diagrams. According to the In vitro release studies, three 
nanoemulsions which exhibited fast drug release were used to prepare acetazolamide nanoemulsions with higher water content (59%). The six 
nanoemulsions at either water content (39 or 59%) were evaluated for their physicochemical properties and ex- vivo corneal permeability. In 
addition, Draize rabbit eye irritation test was performed. Moreover, biological evaluation of acetazolamide nanoemulsions for their intraocular 
pressure lowering activity on glaucomatous albino rabbits was carried out. 
Results: Isopropyl myristate nanoemulsion prepared with cremophor EL and transcutol P exhibited the fastest drug release among all isopropyl 
myristate nanoemulsions. Oleic acid nanoemulsion prepared with mixture of tween 80 and cremophor EL as surfactants together with transcutol P 
showed the fastest drug release among other oleic acid nanoemulsion formulae. Similar results were also observed for peanut oil nanoemulsions. 
The above mentioned formulations either at 39% or 59% water content showed acceptable physicochemical properties and higher acetazolamide 
permeability coefficient through goat corneas than that reported for the free drug. They also were non irritant to rabbit eye. Therapeutic efficacy 
testing revealed that peanut oil nanoemulsion at 39% water content showed better and prolonged intraocular pressure lowering effect relative to 
either commercial brinzolamide eye drops (Azopt®) or the commercial oral acetazolamide tablet (Cidamex®). 
Conclusion: Acetazolamide was successfully formulated in nanoemulsion form which revealed high therapeutic efficacy in treatment of glaucoma 
together with prolonged effect. 
Keywords: Acetazolamide, Glaucoma, Nanoemulsion, Topical ophthalmic formulation, Ocular irritation. 
 
INTRODUCTION 
Glaucoma, one of the leading causes of irreversible ablepsia in the 
world, is estimated to be suffered by 70 million people. It generally 
occurs in people aged above 40, but it may also influence the visual 
acuity of much younger people, even children [1]. Glaucoma is an 
ophthalmic disorder characterized by an increase in intraocular 
pressure (IOP), which results in a damage to the optic disc and visual 
field disturbances. Increase in IOP (above 21 mmHg or 2.8 kPa) is a 
consequence of an imbalance between the production and drainage 
of aqueous humor.  
Carbonic anhydrase inhibitors (CAIs), as a mainstay in the medical 
treatment of glaucoma, have been used since 1954 [2], owing to 
their ability to lower IOP by reducing aqueous humor formation in 
the ciliary body. 
Amongst the available CAIs, acetazolamide (ACZ) is still the most 
effective drug for the treatment of glaucoma [3]. Yet, it is not 
available in market as topical ophthalmic formulation due to two 
major problems that hinder the topical effectiveness of ACZ which 
are its poor aqueous solubility (0.7 mg/ ml) and low permeability 
coefficient of (4.1 × 10−6 cm/ sec). To obtain the desired lowering in 
IOP, large oral doses of ACZ are used which lead to unpleasant 
systemic side effects such as central nervous system depression, 
renal failure, diuresis, vomiting, anorexia, and metabolic acidosis [4, 
5]. Thus, to abolish systemic side effects many attempts were 
performed to formulate ACZ in topical dosage forms with higher 
effectiveness as ophthalmic application of drugs remains the 
primary and patient well accepted administration route for the 
treatment of various eye diseases.  
These include topical formulations of ACZ solution in the form of 
sodium salt [3], contact lenses containing ACZ [6], aqueous ACZ 
solution using 2-hydroxypropyl-β-cyclodextrin [7], aqueous ACZ 
solution using cyclodextrins in combination with bio adhesive 
polymers, penetration enhancers, and co-solvents [8] and polymeric 
suspensions of ACZ containing viscolyzers and penetration 
enhancers [9]. However, all these attempts are not devoid of pitfalls 
including poor patient compliance and difficulty of insertion, as in 
contact lenses and tissue irritation, as well as damage and 
toxicological complications caused by penetration enhancers [10]. 
More recent attempts investigated incorporation of ACZ in vesicular 
drug delivery systems for ocular topical therapy. Niosomes have 
been reported as a possible approach to improve the low corneal 
penetration and bioavailability characteristics of ACZ [11], topical 
ocular formulation of ACZ using large unilamellar [12] and 
multilamellar [13] liposomes as a vehicle and a trial to formulate 
ACZ in nanosized emulsion [14] have also been reported in 
literature. For several years, nanoemulsions (NEs) have been 
investigated as new drug delivery systems, and their potential uses 
in ophthalmology have been studied by several research teams [15]. 
Formulations based on NEs have several interesting characteristics 
such as enhanced drug solubilization, good thermodynamic stability 
and ease of preparation [16, 17]. However, the most critical problem 
regarding the NE based drug carriers is the toxicity of the 
components. Recent efforts have been focused on how to decrease 
or eliminate the toxicity or irritation of the NE formulations [15]. 
The objective of the present study was to formulate ACZ in the form 
of NE for topical ocular administration of the drug using ocular safe 
components. The NE form is thought to offer a sustained release 
effect and high penetration of the drug through the cornea. This 
would therefore provide the advantages of conventional eye drops 
(ease of application and high patient compliance) and eliminate 
their disadvantages (low bioavailability and frequent 
administration). 
MATERIALS AND METHODS 
Materials 
ACZ (99.9% purity) was obtained from Chemical Industries 
Development Pharmaceutical Company (CID), Egypt. Tween 80, 
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tween 20, propylene glycol (PG), oleic acid, castor oil, potassium 
dihydrogen phosphate, disodium hydrogen phosphate and sodium 
chloride were obtained from Gomhorya Company, Egypt. Peanut oil 
(arachis oil) was obtained from Nefertari Body Care, Egypt. 
Transcutol P (diethylene glycol monoethyl ether) was kindly 
donated by Gattefosse, France. Isopropyl myristate (IPM) was 
supplied by Sigma Chemical Co., USA. Cremophor EL (polyoxyl 35 
castor oil) was kindly donated by BASF, Germany. All other 
chemicals were of analytical grade. 
Methods 
Determination of ACZ saturated solubility in different NE 
components 
To find out appropriate surfactants, cosurfactants and oils that have 
good solubilizing capacity of ACZ, the solubility of ACZ in various 
components was measured. Surfactants employed were tween 80, 
tween 20, labrasol, brij 30 and cremophor EL. Cosurfactants used 
were PG and transcutol P. Oils employed were IPM, oleic acid, 
peanut oil and castor oil.  
In screw capped vials, an excess amount of ACZ was added to 2 ml of 
each selected NE component, and shaken in a thermostated shaking 
water bath (GFL 1083, Germany) at room temperature for 24 h. The 
suspensions were centrifuged at 3000 rpm for 30 min. Then, 1 ml of 
the supernatant was dissolved in 50 ml dimethyl sulfoxide (DMSO) 
and diluted to 100 ml using phosphate buffer saline (PBS) pH 7.4. 
Concentration of ACZ was determined spectrophotometrically at 
λmax 263 nm (Shimadzu UV-1601 PC, Kyoto, Japan). Each 
determination was performed in triplicate. The blanks for the 
experiments were prepared using 1 ml of pure substance dissolved 
in DMSO and diluted to 100 ml using PBS. 
Construction of pseudo-ternary phase diagrams 
Pseudoternary phase diagrams were constructed to obtain the 
components and their concentration ranges that can result in large 
existence area of plain NE. 
The pseudoternary phase diagrams of oil (IPM, oleic acid and peanut 
oil), surfactant (tween 80 and cremophor EL), and cosurfactant (PG 
and transcutol P) were developed using water titration method at 
25°C [18] at various surfactant/cosurfactant (S/COS) ratios (km 
ratios).  
In case monophasic, clear, and transparent mixtures were visualized 
after stirring, the samples were marked as points in the phase 
diagram. The area covered by these points represents the region of 
NE and was measured using AutoCAD® software (Autodesk, Inc., 
San Rafael, CA, USA). 
Preparation of ACZ loaded NEs 
From the constructed pseudoternary phase diagrams, eighteen NEs 
were selected at the predetermined optimum km ratio in the area of 
dilutable NEs in order to prepare stable NE formulae that withstand 
physiological dilution process occurring after ocular administration.  
To prepare drug loaded NEs, 1% w/w ACZ was sonicated with 
surfactant / cosurfactant / oil blends until complete dissolution of 
the drug then the aqueous phase containing 3% w/w DMSO was 
added dropwise to prepare NEs containing 39% w/w aqueous 
phase, while to prepare NEs at 59% water content, aqueous phase 
containing 20% DMSO was used. DMSO was added in order to 
prevent any precipitation of the drug after the addition of the 
aqueous phase. Drug loaded formulae were preserved with 
benzalkonium chloride (0.01%) [19]. 
Examination under cross polarized microscope 
In order to exclude liquid crystalline systems and to verify the 
isotropic behavior of NEs, all formulae were examined under cross 
polarized microscope (Olympus, Japan) to insure the absence of 
birefringence [20, 21]. 
In vitro release studies of ACZ from different formulae 
In vitro drug release studies of the developed drug loaded NEs (0.5 g 
each) were performed in triplicate in a USP dissolution tester 
apparatus type II (Hanson SR8 - Plus, USA) at 34 ± 0.5 ºC to simulate 
the ocular surface temperature [22]. The receptor phase was 
composed of 100 ml PBS pH 7.4 and it was constantly stirred at 50 
rpm throughout the experiment. Drug release was performed 
through a semipermeable membrane (Spectra Por©). At definite 
time intervals, 1 ml of the receptor phase was withdrawn and 
replaced by fresh buffer to maintain a constant volume. Drug 
concentration was determined spectrophotometrically at 263 nm. 
Percent of released drug was plotted versus time. The mean 
dissolution rate (MDR) was calculated for each NE formulation 
according to the following equation:  
MDR = �∑ ∆Mjnj=1 �∆t�/n 
Where n is the number of dissolution sample times, ∆t is the time at 
midpoint between t and t −1 (easily calculated with (t + t −1)/2) and ∆Mj 
is the additional amount of drug dissolved between tj and t−1 [23]. 
The drug release profiles were fitted to zero order, first order and 
Higuchi diffusion models to estimate the best fitting kinetic model 
having the highest correlation coefficient.  
Physicochemical characterization of NEs 
Evaluation of rheological properties 
Viscosity of the prepared formulae was determined using cone and 
plate viscometer (Brookfield, USA), spindle 40. Shear rate in the 
range of (37.5 - 375 S-1) was applied and the resulting shear stress 
was measured. 
Droplet size determination 
The mean droplet size (MDS) was determined by photon correlation 
spectroscopy (PCS) using a Zetasizer Nano ZS (Ver.6.20, Malvern 
Instrument Ltd., Worcestershire, England). All measurements were 
performed in triplicate at room temperature (25 ºC) at 90◦  to the 
incident beam. 
pH measurements 
pH of the NE formulations was measured by pH meter (JENWAY 
model 350, JENWAY Ltd., UK). 
Refractive index measurements  
Refractive index was determined at 25 ºC using refractometer 
(M 46.17 / 63707 Higler and Walts Ltd., England). 
Surface tension measurements 
Surface tension measurements were carried out room temperature 
using a thermostatically controlled processor tensiometer K100 
(Kruss GmbH, Germany) provided with a Du Nouy ring (ring radius 
9.545 mm, wire diameter 0.37 mm). 
Osmolality determination 
Osmolality was measured using Micro Osmometer (model 3300, 
Advanced Instruments Inc., USA).  
Thermodynamic stability studies 
The thermodynamic stability of the formulae was evaluated on three 
phases according to the protocol designed by Shafiq et al. [24]. 
Initially, the formulae were subjected to six heat (45 ºC) – cool (4 ºC) 
cycles with storage for 48 h at each temperature. Then, they were 
centrifuged at 3500 rpm for 30 min and finally exposed to three 
freeze (−21 ºC) – thaw (25 ºC) cycles with storage for 48 h at each 
temperature. 
Ex vivo corneal permeation studies using goat corneas 
Goat corneas were used to study the permeation across the corneal 
membrane. Whole eyeballs of goats were procured from a slaughter 
house and transported to laboratory in normal saline maintained at 
4 ºC. The corneas were carefully removed along with a 5 – 6 mm of 
surrounding scleral tissue and washed with cold saline. The washed 
corneas were kept in cold freshly prepared solution of simulated 
tear fluid (STF) of pH 7.4 [25]. The study was carried out by using 
Franz-diffusion cells in such way that epidermal side was in an 
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intimate contact with formulation in the donor compartment. The 
corneal area available for diffusion was 0.785 cm2. The receptor 
compartment was filled with STF pH 7.4 at 34°C ± 0.5 ºC. The 
receptor medium was stirred at 50 rpm. The samples were 
withdrawn at different time intervals and replenished with an equal 
volume of STF pH 7.4 at each time interval.  
The permeation study was carried out for 4 h, and samples were 
analyzed for ACZ spectrophotometrically at 263 nm. Results were 
expressed as the mean of three experiments ± S. .D.  
The amount of drug permeated per unit area through excised cornea 
(µg / cm2) versus time (h) was plotted and the permeation 
parameters of ACZ in the different formulae were calculated [26-28].  
The steady state flux (J) values across excised cornea were evaluated 
from the linear ascents of the permeation graphs by means of the 
relationship 
J = dQ /dt A (µg / cm2 hr) 
The permeation coefficient P was calculated as:  
P = J / C0 × 60 × 60 (cm / s) 
Where C0 represents the initial drug concentration in donor 
compartment (µg / cm3) 
The drug absorption lag times (indicating the time taken by the drug 
to saturate the cornea and to reach the receiving compartment) 
were calculated from x-axis intercept values of regression lines. 
Corneal hydration 
At the end of the experiment, each cornea (freed from adhering 
sclera) was weighed, soaked in 1 ml methanol, dried overnight at 80 
°C, and reweighed. From the difference in weights, corneal hydration 
was calculated [29-31]. 
Ocular irritation studies 
Animal housing and handling 
Qualitative as well as quantitative estimation of ocular irritancy of ACZ 
loaded NE formulations was studied on adult male New Zealand albino 
rabbits weighing about 2 – 3 kg. The protocol of the study was 
approved by the Research Ethics Committee in the Faculty of 
Pharmacy, Cairo University, Egypt. The rabbits were housed singly. 
The standard environmental conditions, i. .e. dark: light cycle 12 h 
each, 20 – 25 ◦C temperature and 40 – 70% relative humidity were 
maintained. Rabbits were fed with standard pellet diet and water was 
provided ad libitum. All the animals used in the experiment were 
healthy and free from any clinically observable ocular abnormalities. 
Ocular irritancy test 
The test was conducted as per the Modified Draize Test [32, 33] on a 
group of 12 New Zealand albino rabbits. All the glass wares used in 
the experiments were sterilized by autoclaving (Remi Equipments 
Pvt. Ltd., Mumbai, India). All applied formulations were sterilized by 
filtration technique using 0.22 µm membrane filters (Millipore, 
USA). 25 µl of each formulation was instilled into the lower cul-de-
sac of the eye of each rabbit with the help of needleless syringe. The 
untreated contralateral eye was used as a control. A separate control 
group of two rabbits received normal saline. The eyelids were gently 
held together for about 10 S for avoiding the loss of instilled 
solution. Each animal was observed for ocular reactions (redness, 
discharge, conjunctival chemosis, iris and corneal lesions) at 5, 10, 
15, 30 min and 1, 2, 3, 6, 9, 12, 24 h post instillation. The ocular 
irritancy test was performed by providing 0 (absence) to 4 (highest) 
grades on clinical evaluation scale as described in table 1 [32, 33]. 
Overall ocular irritation index (Iirr) was calculated by summing up 
the total clinical evaluation scores over the observation time points. 
A score of 2 or 3 in any category or Iirr more than 4 was considered 
as an indicator of clinically significant irritation. 
 
Table 1: Modified Draize grading scale for clinical evaluation of ocular irritation. 
Parameter Observation Score 
Conjunctival discharge Normal 0 
Slight discharge 1 
Severe discharge covering a small area around the cornea 2 
Severe discharge covering a large area around the cornea 3 
Conjunctival chemosis Normal 0 
Slight chemosis including nictating membrane 1 
Severe chemosis with eye partially closed 2 
Severe chemosis with eye closed 3 
Conjunctival redness Blood vessels normal 0 
Some blood vessels definitely hyperaemic 1 
Diffuse color, individual vessels not easily discernible 2 
Diffuse beefy red 3 
 
Therapeutic efficacy studies 
Twelve New Zealand albino rabbits weighing 2.0 – 3 kg were 
randomized in groups of four having three in each. Experimental 
glaucoma was induced in the rabbits by an intraocular injection of 
0.25 ml of 2% w/w sodium carboxy methylcellulose [34]. 
The IOP of the rabbits were measured using an indention tonometer 
(Schoetz tonometer, Teufel Germany). Before taking the 
measurement, eyes were anesthetized with 1 – 2 drops of 
benoxinate hydrochloride (Benox®) eye drops. 
The resting glaucomatous IOP was measured twice a day in the 2 
days before drug application. In this way, the normal baseline of 
each animal was established before treatment. All experiments were 
carried out at the same time of the day. 
A single 50 µl dose of 1% ACZ loaded peanut oil NE with 39% and 
59% aqueous content (NE 18a and NE 18b) was applied topically to 
the cornea of the first two groups. In addition, 50 µl aliquots of 
Azopt® (brinzolamide, 1% w/v) were administered to the rabbits of 
the third group for comparison. The fourth group received orally, a 
fraction of ACZ tablet (Cidamex®) equivalent to 9 mg ACZ. All the 
measurements were performed 2 times, at each interval, and the 
mean was calculated. The IOP was measured at 30, 60, 90, 120, 150, 
180, 240, 300 and 360 min.The reduction of IOP versus time plots; 
provide the therapeutic profiles of ACZ NEs versus ACZ tablet and 
1% brinzolamide. These profiles were used to calculate the 
pharmacodynamic parameters: area under the curve (AUC0–6), time 
required to achieve peak IOP reduction (tmax), maximum percentage 
decrease in IOP and the mean residence time (MRT) using WinNonlin® 
software (Ver. 1.5, Scientific consulting Inc., Cary, NC, USA). 
Statistical analysis of the results was performed using one way 
analysis of variance (ANOVA) which was computed with GraphPad 
Instat software (GraphPad software, USA). 
RESULTS AND DISCUSSION 
Determination of ACZ saturated solubility in different NE 
components 
Preliminary ACZ solubility study was carried out for the 
identification of NE components that show highest solubility and 
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thus would be used for preparation of ACZ loaded NEs. table 2 lists 
the solubility of ACZ in different surfactants, cosurfactants and oils. 
 
Table 2: ACZ solubility in different NE components at room 
temperature 
 NE component Solubility (mg/ml) 
Surfactants Tween 20 12.9 ± 0.41 
Tween 80 17.2 ± 0.89 
Cremophor EL 15 ± 0.75 
Labrasol 8.2 ± 0.22 
Brij 30 3.4 ± 0.14 
Cosurfactants Transcutol P 22.4 ± 0.9 
PG 3.7 ± 0.21 
Oils IPM 1.2 ± 0.11 
Peanut oil 9.3 ± 0.24 
Oleic acid 1.6 ± 0.2 
 
Selection of NE components 
For the present study, tween 80 and cremophor EL were used as non 
ionic surfactants, as they showed the highest solubility of ACZ 
among other surfactants. In addition, tween 80 is widely used in 
ophthalmic preparations due to its safety. It is listed for ophthalmic 
preparations in US Pharmacopeia-National Formulary, European 
Pharmacopeia, and the Japanese Pharmacopeia [35]. Moreover, an 
ocular irritation evaluation test was made by Alany et al. [36] and 
classified tween 80 as practically nonirritant. On the other hand, 
according to informations provided by the manufacturer, the 
instillation of 0.05 ml of cremophor EL in the rabbit’s conjunctival 
sac caused only slight reddening of the conjunctiva which 
disappeared within a few hours. It is also reported that the 
application of a 50% aqueous solution of cremophor EL caused 
slight irritation with lacrimation, which disappeared rapidly 
whereas 30% aqueous solution had no irritant effect [37].  
An additional important criterion for selection of the surfactants is 
their HLB values. The HLB value required to form o/w NEs should 
be greater than 10 [38]. Tween 80 and cremophor EL have HLB 
values of 15 and 12–14, respectively. 
Transcutol P and PG were used as cosurfactants. Transcutol P 
showed the highest ACZ solubility among all tested components. It is 
known as common emulsion excipient suitable for dissolving or 
dispersing lipophilic drugs in ocular preparations [39]. Also, an 
ocular irritation study was performed by Ammar et al [19] on ocular 
NEs in which transcutol P was one of its component and they found 
that they were non irritant to rabbit eyes. Furthermore, it is 
reported that solutions of up to 50% PG caused no irritations to 
rabbit eyes, whereas the undiluted application was associated with a 
weak conjunctival redness [40].  
Although peanut oil showed highest ACZ solubility, IPM and oleic 
acid were also used as oil phase in NE in order to study the effect of 
different oil structures on area of NE formation.  
Peanut oil, IPM and oleic acid are structurally different oils. IPM is an 
ester of isopropanol and myristic acid which is a fatty acid of 14 carbon 
atoms. Oleic acid is a monounsaturated fatty acid of chain length of 18 
carbons. Peanut oil is a vegetable oil that consists mainly of triglycerides 
of oleic acid, linoleic acid and linolenic acid, which are C18 fatty acids 
containing 1, 2 and 3 double bonds, respectively.  
Construction of pseudoternary phase diagrams 
Eighteen systems were prepared each at S/COS ratio of 1:1, 2:1, 3:1, 
4:1, 5:1, 7:1 and 9:1; the pseudoternary-phase diagrams were 
mapped with the water titration method at 25 °C to identify the area 
of NE regions.  
As expected from the previously reported data [41], the phase 
behavior of different systems was strongly influenced by the 
molecular volume of the oil incorporated within the NE. It was found 
that, NE regions obtained upon using IPM as an oily phase, were 
larger than in case of oleic acid which in turn were larger than those 
obtained using peanut oil. The latter failed to form NEs with S/COS 
ratios 1:1 and 2:1 (Fig. 1). Such findings coincide with that obtained 
by Aveyard et al who found that if the hydrocarbon chain length of 
the oil being dispersed is considerably less than the length of the 
hydrophobic part of the surfactant used, the oil will significantly 
penetrate the interfacial surfactant layer resulting in more efficient 
spontaneous NE formation and higher oil solubilization [42]. In 
addition, the presence of polar ester groups in oil structure 
decreases the oil hydrophobicity and results in stronger interactions 
between surfactant and oil molecules which lower interfacial 
tension [43, 44] and favor the formation of NE. In contrast, the 
presence of double bonds increases oil hydrophobicity [43]. 
Consequently, oleic acid showed smaller NE regions than that 
showed by IPM due to longer carbon chain, the absence of polar 
ester groups and the presence of one double bond. 
Peanut oil showed the smallest NE regions. This finding could be on 
one hand due to its high triglyceride content which decreases oil 
surfactant interactions to a greater extent and on the other hand due 
to the presence of double bonds in fatty acid chains which lead to an 
increase in oil hydrophobicity and a more complicated spatial 
arrangement of the triglyceride structure [43]. The use of 
cremophor EL as surfactant resulted in smaller NE existence areas 
compared to tween 80 (Fig. 1). In order to increase the oil 
solubilizing capacity of cremophor EL and due to the fact that the 
flexibility of surfactant layer and its ability to partition at higher 
levels into the oil–water interface might be enhanced by combined 
surfactants [45-49], NEs with a mixture cremophor EL and tween 80 
(1:1 weight ratio) were also prepared during the formulation of ACZ 
loaded NEs.  
With respect to the cosurfactants used, the use of transcutol P 
resulted, generally, in higher NE existence areas than those obtained 
using PG. This may be attributed to the longer carbon chain length in 
transcutol P (6 carbons versus 3 carbons in PG) and also due to the 
increase in the number of hydroxyl groups in PG (2 versus 1 in 
transcutol P) which was found to reduce NE existence area. This was 







Fig. 1: Dependency of NE existence area on types of oil, surfactant, 
cosurfactant and surfactant to cosurfactant weight ratio: (a) IPM, 
(b) peanut oil and (c) oleic acid. (T80: tween 80, Cr EL: cremophor 
EL, Trans: transcutol P and PG: propylene glycol) 
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It is evident from Fig. 1 that for systems containing IPM the optimum 
S/COS weight ratio was found to be 3:1 while for systems containing 
peanut oil and oleic acid the optimum S/COS ratio was found to be 9:1. 
Preparation of ACZ NEs 
Eighteen NEs were formulated at the predetermined optimum S/COS 
weight ratio and at 39% (w/w) water content.  
The prepared NEs were loaded with 1% (w/w) ACZ. The NE 
compositions are shown in table 3. 
Examination under cross polarized microscope 
In all previously prepared NEs, no liquid crystalline domain was 
observed. All the formulations appeared dark when viewed between 
crossed polarizers indicating isotropic nature of NEs. 
 
Table 3: Composition of ACZ loaded NEs**. 
Component 
(% w/w) 
IPM Oleic acid Peanut oil T 80 Cr EL PG Trans 
NE 1 6 …. …. 40.5 …. 13.5 …. 
NE 2 6 …. …. 40.5 …. …. 13.5 
NE 3 6 …. …. …. 40.5 13.5 …. 
NE 4 6 …. …. …. 40.5 …. 13.5 
NE 5 6 …. …. 20.25 20.25 13.5 …. 
NE 6 6 …. …. 20.25 20.25 …. 13.5 
NE 7 …. 3 …. 51.3 …. 5.7 …. 
NE 8 …. 3 …. 51.3 …. …. 5.7 
NE 9 …. 3 …. …. 51.3 5.7 …. 
NE 10 …. 3 …. …. 51.3 …. 5.7 
NE 11 …. 3 …. 25.65 25.65 5.7 …. 
NE 12 …. 3 …. 25.65 25.65 …. 5.7 
NE 13 …. …. 3 51.3 …. 5.7 …. 
NE14 …. …. 3 51.3 …. …. 5.7 
NE 15 …. …. 3 …. 51.3 5.7 …. 
NE 16 …. …. 3 …. 51.3 …. 5.7 
NE 17 …. …. 3 25.65 25.65 5.7 …. 
NE 18 …. …. 3 25.65 25.65 …. 5.7 
** All NE formulae contain 1% ACZ and 39% water 
 
In vitro release studies of ACZ from different formulae 
The In vitro drug release profiles of the drug loaded IPM, oleic acid 
and peanut oil based NEs are graphically illustrated in Fig. 2. To 
facilitate comparison between release behaviors of different NE 
formulae, MDR was calculated and the results are represented in 
table 4. 
The release results of IPM NEs revealed that formulae containing 
cremophor EL surfactant (NE3, NE 4) showed higher drug release 
than those prepared using tween 80 (NE1, NE2). This finding can be 
attributed to the higher thermodynamic activity of the drug in NE 3 
and NE 4 as ACZ is more soluble in tween 80 than in cremophor EL. 
This was in agreement with Rhee et al [52].  
For oleic acid and peanut oil NEs, the results revealed that formulae 
containing mixture of tween 80 and cremophor EL surfactant 
showed higher drug release than those prepared using either tween 
80 or cremophor EL alone. This can be correlated to the fact that 
combined use of surfactants is significantly more effective in 
generating NEs, as it results in smaller droplet size.  
The decrease in droplet size resulted in an increase of total number 
of oil globules and subsequent increase in their surface area which 
led to an increase in drug release. 
This finding was observed in oleic acid and peanut oil NEs but not in 
NEs prepared using IPM which probably could be referred to the 
larger molecular volume of oleic and peanut oil which makes their 
nano emulsification more difficult.  
For all prepared NEs, drug release from PG NEs was significantly 
lower than those containing transcutol P as cosurfactant. This is 
probably due to the higher viscosities of PG NEs than transcutol P 
NEs (Table 4) This was in agreement with Idrees et al [53]. 
Mathematical modeling of the data revealed that the dissolution 
profiles of all formulae followed Higuchi diffusion model. 
Preparation of ACZ NEs with different aqueous phase content 
NEs 4, 12 and 18 that exhibited highest drug release among NEs 
prepared using different oils were chosen to prepare NEs with 59% 
aqueous phase content in an attempt to prepare stable NEs with 
minimum surfactant concentration and to study the effect of 
increasing water concentration on the physico-chemical properties 







Fig. 2: Release profiles of ACZ from different NE formulations: 
(a) IPM NEs, (b) oleic acid NEs and (c) peanut oil NEs 
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Table 4: The effect of NE composition and viscosity on release 
efficiency represented by MDR 
Formulation Viscosity (cp) MDR 
NE1 486.6 0.18 
NE2 157 0.75 
NE3 1497 0.88 
NE4 334.8 1.8 
NE5 465.6 0.73 
NE6 282.3 0.81 
NE7 518 0.42 
NE8 371.5 0.58 
NE9 1048 0.68 
NE10 805.7 0.72 
NE11 685.4 0.73 
NE12 402.9 0.74 
NE13 1355 0.56 
NE14 831.9 0.66 
NE15 2736 0.49 
NE16 1778 0.62 
NE17 1758 0.83 
NE18 1135 1.01 
 
 
The same S/COS/oil ratios in these formulae were used to prepare 
NEs of higher water content (59% water content) (Table 5). The 
formulae with lower (39%) and higher (59%) were subjected to 
various physicochemical characterization. 
Physicochemical characterization of NEs 
Evaluation of rheological properties 
It has been assumed that ophthalmic instillation of a formulation 
should influence the normal behavior of tears. Systems with low 
viscosity allow good tolerance with little blinking pain. In contrast, 
systems with enhanced viscosity, although less tolerant, induce an 
increase in ocular contact time by reducing the drainage rate and, as 
a consequence, improve bioavailability [54].  
ACZ NEs exhibited a Newtonian behavior. The viscosity values of 
studied ACZ NEs at minimum shear rate were shown in (Table 6). 
From the viscosity results, it could be observed that NE formulae 
prepared with IPM showed the lowest viscosities while that 
prepared with peanut oil showed the highest viscosity values. The 
viscosity of all NE formulae decreased upon dilution with aqueous 
phase.
Table 5: Composition of NEs exhibited highest drug release (NE 4, 12 and 18) at lower 39% and higher 59% water content. ** 
Component (% w/w) NE 4 a NE 4 b NE 12 a NE 12 b NE 18 a NE 18 b 
IPM 6 4 …. …. …. …. 
Oleic acid …. …. 3 2 …. …. 
Peanut oil …. …. …. …. 3 2 
T 80 …. …. 25.65 17.1 25.65 17.1 
Cr EL 40.5 27 25.65 17.1 25.65 17.1 
Trans 13.5 9 5.7 3.8 5.7 3.8 
Water 39 59 39 59 39 59 
** All NEs contain 1% (w/w) ACZ. 
 
Droplet size determination 
The selected NEs showed MDS of 23.81 - 90.26 nm (Table 6). This 
small MDS could be related to the penetration of the cosurfactant 
molecules into the surfactant film. This would decrease the fluidity 
and surface viscosity of the interfacial film, lower the radius of 
curvature of the droplets and thus form transparent systems [55]. 
Three oils (IPM, oleic acid and peanut oil) were investigated at two 
different ratios (6, 4 in NEs prepared with IPM and 3, 2 % w/w in 
case of oleic and peanut oil). With respect to the effect of oil on MDS, 
it was found that IPM results in the smallest MDS followed by oleic 
acid and peanut oil which shows the largest MDS. This was 
consistent with the molecular volume of the different oils. The 
greater the molecular volume of oil, the lower its penetration in the 
S/COS interfacial film. Therefore, peanut oil which is a triglyceride 
with high molecular volume revealed highest MDS [56, 57].  
For NEs containing the same oil, it was found that the larger the oil 
percentage, the larger the MDS. This finding was consistent with a 
previous report showing that the MDS increases significantly when 
more oil is incorporated owing to the expansion of oil droplet of the 
NE by further addition of the oil [58]. 
pH measurements 
The ideal pH for maximum comfort when an ophthalmic preparation is 
instilled in the eye should be in the range of 7.2  ± 0.2 [19]. In some cases, 
the instillation of a solution with a pH different from tears causes 
irritation and painful sensation. This depends on the instilled volume, the 
buffering capacity, the composition and the contact time of the solution 
with the eye surface [19]. Different pH values can be tolerated if the 
preparation is not or is only very slightly buffered because in this case 
the limited buffering capacity of the tears is able to adjust the pH to 
physiologic levels on administration [59]. The pH of therapeutic 
substances applied as eye drops can vary from 3.5 to 8.5 [19].  The pH 
values of the developed NEs were in the range of 4.9 to 5.5 (Table 6) 
being therefore adequate to their application to the eye. The 
obtained values were also able to preserve drug stability as ACZ is 
highly unstable at an alkaline pH and has maximum stability at pH 4 
to 5 [60, 61]. 
Refractive index measurements  
Refractive index measurements detect possible impairment of vision 
or discomfort to the patient after administration of eye drops [59]. 
Refractive index of tear fluid is 1.340 to 1.360 [59]. It is 
recommended that eye drops should have refractive index values 
not higher than 1.476 [62].  
Table 6 shows that ACZ NEs had refractive index values ranging 
from 1.347 to 1.366 which are within the recommended values. 
Surface tension measurements 
The surface tension values obtained for the NEs were in the range of 
32.5 - 38.7 mN/m (Table 6) which is lower than the physiological 
value of the lachrymal fluid surface tension which ranges from 40 to 
50 mN/m [59]. This result was expected because of the large 
amounts of surfactants used in the preparation of NE 
Administration of eye drops with lower surface tension than that of 
the lachrymal fluid resulted in destabilization of the tear film [63, 
64]. The low surface tension obtained for the developed NEs, thus, 
destabilized the tear film which can guarantee a good spreading 
effect on the cornea and mixing with the precorneal film 
constituents, thus possibly improving the contact between the drug 
and the corneal epithelium [65]. 
Osmolality Determination 
The osmolality of the prepared ACZ NEs ranged from 860 to 
1750 mOsm/kg (Table 6). A study on human tear osmotic pressure 
stated that the osmolality of lachrymal fluid is between 280 and 
293 mOsm/kg on waking. As a result of evaporation when the eyes 
are open, osmolality may vary between 231 and 446 mOsm/kg [66]. 
Depending on the drop size, solutions with an osmolality lower than 
Morsi et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 11, 227-236 
233 
100 mOsm/kg or higher than 640 mOsm/kg are irritant. However, 
Haße and Keipert [65] formulated ocular microemulsions with 
osmolality ranged from 1,200 to 2,400 mOsm/kg and found that they 
were nonirritant using hen’s egg test on the chorioallantoic membrane 
and Draize test on rabbits’ eyes. In addition, the original osmolality was 
restored 1 or 2 min after instillation of the nonisotonic solution [67]. 
Thermodynamic stability studies 
The stability of the developed systems was evaluated via heat–cool 
cycles, centrifugation, and finally freeze–thaw cycle stress tests. The 
systems passed the alternate heat–cool cycles and remained clear. 
The second phase exploring the effect of centrifugation revealed 
promising physical stability; no signs of creaming, phase separation 
or cracking. Cloudiness was observed when the systems were frozen 
at −21 °C.  
However, their clarity was recovered upon thawing. Similar findings 
were reported by Ammar et al. [19] and Tayel et al. [68] who related 
this transient instability to the coagulation of the internal phase at 
such low temperature and to the pressures exerted by the ice 
crystals on the dispersed globules and the adsorbed layers of S/COS. 
  
Table 6: Physicochemical properties of ACZ NEs. 
Formulation Viscosity (cp) Droplet diameter (nm) Refractive index pH Surface tension (mN/m) Osmolality 
(mOsm/Kg) 
NE 4 a 334.8 40.86 1.362 5.2 32.5 1195 
NE 4 b 15.7 27.75 1.347 5.3 35.8 860 
NE 12 a 402.9 63.78 1.358 4.9 34.7 1750 
NE 12 b 193.6 27.76 1.348 5.1 38.7 1246 
NE 18 a 1135 90.26 1.366 5.2 33.2 1586 
NE 18 b 83.7 23.81 1.358 5.5 36.9 1070 
 
Ex vivo corneal permeation studies using goat corneas 
ACZ is a poorly water- and lipid- soluble drug. Its poor lipid 
solubility limits its transit through the corneal epithelium and 
endothelium, whereas poor aqueous solubility prevents the transit 
through the hydrophilic stroma [69]. From the results of the present 
study, it is obvious that water content and oil type in NEs affect ACZ 
permeation through goat corneas. 
It was found that the increase in water content results in a decrease 
in permeation (Fig. 3). This may be attributed to the decrease in 
concentration of surfactants and cosurfactant in NE which act as 
permeation enhancers by increasing the membrane permeability 
and consequently the drug uptake. This result is consistent with 
Baroli et al. [70], Peltola et al. [71], Yuan et al. [58] and Zhu et al [72]. 
In addition, the increase in water content (39 to 59 %) resulted 
consequently in a decrease in the oil percentage in the formula thus 
the contact area between oil and lipophilic surface of corneal 
epithelium decrease. The increase in oil content in NEs resulted in 
more oil which was available to adhere to lipophilic surface of 
corneal epithelium and therefore could promote ACZ permeation.  
By comparing the effect of oil type, it was evident that peanut oil 
showed the highest permeation followed by oleic acid then IPM. This 
observation could be attributed to ACZ solubility in these oils (Table 
2) in addition to the differences in oils’ lipophilicity. Peanut oil 
which is a triglyceride is the most lipophilic among the studied oils, 
so its nanodroplets are more likely to adhere to the surface of 
corneal epithelium and consequently resulted in an increased ACZ 
permeability through cornea either by lipophilic association through 
the corneal membrane or via endocytosis [73, 74]. The analysis of 
data from table 7 indicates that NE prepared with peanut oil at 39% 
aqueous phase content (NE 18a) was the most efficient in drug 
permeation according to the cumulative amount permeated per unit 
area, steady state flux, and permeability coefficient values. 
A six fold increase in ACZ permeability coefficient was obtained in 
case of NE 18a as if compared with permeability coefficient of ACZ 
stated in literature. 
Corneal hydration 
Corneal hydration was calculated to evaluate the damage to corneal 
tissue. Normal cornea has a hydration level of 75 to 80% [75]. An 
alteration in this level indicates damage to the endothelium or 
epithelium. Corneal hydration of all of the formulations was between 
75 to 80%, which indicated that the formulations did not cause any 




Fig. 3: ACZ permeation through goat corneas from different NEs: 
(a) NEs prepared at 39% water content and (b) NEs prepared at 
59% water content 
 
Table 7: Comparison of ACZ NEs in terms of permeation parameters obtained from ex vivo permeation studies using goat cornea. 








NE 4a 2232.58 ± 76.09 30 591.1 1.64×10-5 
NE 12a 3057.32 ± 126.21 30 822.1 2.28×10-5 
NE 18a 3681.51 ± 144.7 0 852.5 2.36×10-5 
NE 4b 1644.54 ± 59.5 60 422.6 1.17×10-5 
NE 12b 2167.8 ± 74.19 60 588.9 1.64×10-5 
NE 18b 2448.11 ± 100.28 60 727.5 2.02×10-5 
 
 
Ocular irritation test 
According to the scores of the Modified Draize Test (Table 1), the 
application of NEs revealed a very slight redness of the 
conjunctiva and a slight reflex lachrymation but no chemosis 
during the first 0.5 h after application of NE formulations with 
39% aqueous content. In none of the six rabbits did the Iirr score 
exceed 4 at any time (Table 8). It has to be noted that 
lachrymation decreased until complete disappearance 1 h post 
administration while redness completely disappeared after 2 h. In 
case of NE formulae prepared with 59% aqueous content, rabbits 
showed very slight lachrymation after instillation which 
disappeared completely within 15 min and no signs of chemosis or 
redness were observed (Fig.4). 
From the above results, it is evident that the NE formulations were 
non irritant and could be tolerated by the rabbit eye. Taking into 
consideration that the rabbit eye is more susceptible to irritant 
substances than the human eye [76], this result could be considered 
very promising. 
 
Table 8: Observed irritation scores for different formulations 
Formulation Time for observing total Iirr (min) 
5 10 15 30 60 120 
NE 4 a 1 1.5 2 1.5 0.5 0 
NE 12 a 1 1 2 1.5 0.5 0 
NE 18 a 0.5 1 1.5 2 0.5 0 
NE 4 b 0.5 0.5 0 0 0 0 
NE 12 b 1 0.5 0 0 0 0 
NE 18 b 1 0.5 0 0 0 0 




Fig. 4: Ocular irritation index of different formulations: (a) NEs 
prepared at 39% water content (b) NEs prepared at 59% water 
content 
Therapeutic efficacy studies 
Fig. 5 represents the percent decrease of IOP with respect to the 
baseline in glaucomatous rabbits versus time. It is evident from Fig. 
5 that NE 18a shows optimum pharmacodynamic parameters. The 
calculated pharmacodynamic parameters namely; AUC0–6 (area 
under the percentage decrease in IOP – time curve), tmax (time 
required to achieve maximum decrease in IOP), maximum % 
decrease in IOP and MRT (mean residence time) are listed in table 9.  
 
 
Fig. 5: Percentage decrease in IOP after administration of NE 
18a, NE 18b, Azopt® eye drops and Cidamex® tablet 
 
Table 9: The calculated pharmacodynamic parameters after administration of NE 18a, NE 18b, Azopt eye drops and Cidamex tablet. 
Formulation Max. % decrease in IOP t max (h) AUC0–6 MRT 
NE 18 a 31.96±1.52 1.2±0.29 152±1.87 7.5±1.02 
NE 18 b 29.9±0.01 1.7±0.29 104.4±5.5 4.07±0.184 
Azopt 33.93±1.57 1.5±0 83.96±7.86 2.2±0.25 
Cidamex 24.01±0.02 1.5±0 75.5±7.55 3.13±0.18 
 
Considering the parameter AUC0–6 as a measure of the drug ocular 
bioavailability, it is evident that the value of this parameter was 
ranked in the following order: NE 18a, NE 18b, Azopt® and finally 
Cidamex®. By applying ANOVA statistical test, the differences were 
statistically significant (p < 0.05) with the exception of Azopt® and 
Cidamex® where variation among them was considered non 
significant (p > 0.05).  
In the view of the current result, it could be concluded that both ACZ 
NE formulae had higher bioavailability than either Azopt eye drops 
or Cidamex tablets where NE 18a showed the highest therapeutic 
activity with AUC 1.8 and 2 times higher than that of Azopt drops 
and Cidamex tablet respectively followed by NE 18b which showed 
AUC 1.2 and 1.4 times higher than that of Azopt drops and Cidamex 
tablet respectively. Higher AUC obtained by NE formulation is 
probably because of the penetration enhancement effect of NEs 
which could revealed to removal of mucous layer and disruption of 
tight junctional complexes of corneal tissue by NEs [8, 77].  
Although, the effect of NE 18b on ACZ permeability is less 
pronounced than in NE 18a which is consistent with the results 
obtained from ex- vivo permeation study, it shows greater AUC than 
that observed in case of brinzolamide (Azopt®) which is known to 
be intrinsically more permeable than ACZ [3].  
With respect to the duration of IOP reduction, it is evidenced from 
Fig.5 that both NE formulae showed more prolonged effect than that 
shown by Azopt® or Cidamex®. This result was consistent with the 
calculated MRT (Table 9) as NE 18a had MRT 3.4 and 2.4 times 
higher than those of Azopt® and Cidamex® respectively. NE 18b 
showed MRT 1.85 and 1.3 times higher than that shown by Azopt® 
and Cidamex® respectively. 
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The more prolonged IOP lowering effect exhibited by NE 18a over NE 
18b could be correlated to higher viscosity of the former NE which 
increases the ocular residence time. Also, higher oil content in NE 18a 
could result in a more significant contact time and area with the cornea.  
It was found that no change in IOP was observed in the untreated 
eye during the course of measurement in any of the two NEs. Thus, 
indicating that ACZ NEs exerted a local action within the eye and the 
observed IOP lowering activity is not because of any systemic 
absorption followed by subsequent redistribution. 
The results of this bioavailability study lead to a conclusion that 
formulation of ACZ as NE resulted in an improvement of the 
therapeutic efficacy of the drug. This improvement is associated 
with a decrease or disappearance of the systemic side effects of ACZ 
due to the local action exerted by ACZ NEs.  
CONCLUSION 
ACZ NEs were prepared successfully using IPM, oleic acid and 
peanut oil at 39% water content. ACZ release rate from NEs were 
dependent on the type of surfactant and cosurfactant used in NE 
preparation. NE 4, NE 12 and NE 18 showed highest drug release 
among other NEs. These NEs were prepared at higher water content 
of 59%. All prepared NEs showed acceptable physicochemical 
properties, thermodynamic stability and they were non irritant to 
rabbits’ eyes. NEs improved ACZ permeation across goat corneas 
with 6 times improvement in permeation coefficient of ACZ when 
incorporated in NE 18a. NE 18a showed fast onset of IOP lowering 
activity and prolonged effect as well as enhanced drug 
bioavailability compared to ACZ tablets and brinzolamide eye drops. 
Thus, ACZ in NE 18a offers an intensive treatment of glaucoma with 
a decrease in number of instillation per day and a decrease or 
disappearance of systemic side effects of ACZ with an improvement 
in patient compliance. 
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